Clinical trials: Patients With Type 2 Diabetes
T2DM
Efficacy and Safety of Gemigliptin 50mg qd Added in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride and Metformin
After a screening, a 2-week, single-blind placebo run-in, 174 patients will be randomized in a 1 : 1 ratio to the addition of either once-daily Gemigliptin 50 mg or placebo to ongoing stable doses of glimepiride in combination…
- Trial name
- NCT01990469
- Testing
- Gemigliptin
- Volunteers
- 219 people
- Sponsor
- LG Life Sciences
Type 2 Diabetes Mellitus
Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone
This trial is to evaluate the efficacy and safety of CWP-0403 compared to Sitagliptin by proving non-inferiority in patients with type 2 Diabetes Mellitus insufficiently controlled with metformin alone.
- Trial name
- CWP-DIANA-302 (NCT01529541)
- Testing
- Anagliptin, Sitagliptin
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- JW Pharmaceutical
Type 2 Diabetes Mellitus
Safety, Tolerability and Pharmacodynamics of CYT013-IL1bQb in Patients With Type 2 Diabetes
The purpose of this clinical trial is to test safety and tolerability of a vaccine targeting Interleukin-1 beta in patients with type 2 diabetes.
- Trial name
- NCT00924105
- Testing
- CYT013-IL1bQb
- Where
- 3 sites in Germany, Switzerland
- Volunteers
- 48 people
- Sponsor
- Cytos Biotechnology AG
Diabetes Mellitus, Type 2
A Study of LY3108743 in Healthy Participants and Participants With Type 2 Diabetes
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY3108743 in healthy participants and in participants with type 2 diabetes.
- Trial name
- NCT01995656
- Testing
- LY3108743 - Capsule, LY3108743 - Solution
- Where
- Singapore
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Growth Hormone Deficiency, Neoplasms
A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical Parameters
The aim of this study is to look at the long-term safety and clinical parameters of somapacitan in paediatric participants with growth hormone deficiency under routine clinical practice conditions.
- Conditions
- Growth Hormone Deficiency, Neoplasms, Diabetes Mellitus Type 2
- Trial name
- NCT06709040
- Testing
- Somapacitan
- Where
- United Kingdom
- Volunteers
- 500 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
The Efficacy and Safety of Different Doses of SY-004 in Patients With Type 2 Diabetes Mellitus
This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study in patients with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT04217291
- Testing
- SY-004
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Suzhou Yabao Pharmaceutical R&D Co., Ltd.
Diabetes, Diabetes Mellitus, Type 1
Observational Study to Evaluate the Efficacy and Safety of NovoMix® 30 in Type 1 and 2 Diabetes
This study is conducted in Europe. This observational study is aimed to reflect the post-authorisation experience with insulin analogue (biphasic insulin aspart 30) when used under normal clinical practice conditions in Serbia.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- EFFECTIVE (NCT00699179)
- Testing
- biphasic insulin aspart 30
- Where
- Serbia and Montenegro
- Volunteers
- 2,308 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Pharmacokinetics and Pharmacodynamics Trial With Linagliptin (BI 1356) 5mg in African American Type 2 Diabetic Patients
The objective of this trial is to investigate the pharmacokinetics and pharmacodynamics of linagliptin (BI 1356) 5 mg administered orally in patients with Type 2 diabetes mellitus of African American origin.
- Trial name
- NCT00935220
- Testing
- linagliptin QD (once daily) for 7 days
- Where
- 6 sites in United States
- Volunteers
- 41 people
- Sponsor
- Boehringer Ingelheim
Type2 Diabetes
Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics
This study allows Type 2 diabetics to receive feedback from a continuous glucose monitor (CGM) as part of an educational program designed to help them better manage their glucose levels.
- Trial name
- CGM_IRB2 (NCT03252964)
- Testing
- Continuous Glucose Monitor (CGM), Activity Tracker, Coaching
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Savvysherpa, Inc.
Diabetes Mellitus, Type 2
Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs
Primary Objective: To evaluate the efficacy of an intensive insulin regimen with insulin glargine and insulin glulisine in terms of change in Hemoglobin A1c (HbA1c) level from week 12 (visit 7) to week 24 (visit 10).
- Trial name
- CHANGING (NCT01203111)
- Testing
- INSULIN GLARGINE, INSULIN GLULISINE
- Where
- 10 sites in Algeria, Brazil and 8 more
- Volunteers
- 207 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes
The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, compared to rosiglitazone in lowering overall blood glucose levels in people with type 2 diabetes who have not previously…
- Trial name
- NCT00099918
- Testing
- vildagliptin
- Where
- 2 sites in United States, Germany
- Volunteers
- 717 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
Efficacy and Safety In Poorly Controlled Type 2 Diabetics
The purpose of this study is to gain safety and efficacy information in patients with type 2 diabetes, who have not previously taken any oral antidiabetic medications, and who have an HbA1c value of greater than or equal to 10%…
- Trial name
- NCT00044460
- Testing
- rosiglitazone
- Volunteers
- 142 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes
Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s)
This long term, placebo-controlled trial is intended to assess the efficacy and safety of exenatide, dosed twice a day, in Japanese patients with Type 2 Diabetes who are treated with oral antidiabetic(s) but not well controlled.
- Trial name
- NCT00577824
- Testing
- exenatide
- Where
- 12 sites in Japan
- Volunteers
- 181 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Freestyle Libre-based Education on MDI in T2DM (FreEdoM-2)
Multicenter, Open-label, Randomized Trial to Compare the Effectiveness of Structured Education and Safety of FreeStyle Libre or Self-Monitoring of Blood Glucose (SMBG) in patients with type 2 Diabetes Mellitus using Multiple…
- Trial name
- NCT04926623
- Testing
- FreeStyle Libre 24 weeks, SMBG (22 weeks) and blind CGM (2 weeks)
- Where
- South Korea
- Volunteers
- 159 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Type 2 Diabetes Mellitus
Effect of Oral Combination Therapy in a Single Dosage Form in Patients With Type 2 Diabetes Mellitus
The aim of the study is to determinate the effect of combined oral therapy of long acting metformin/glimepiride in a single dose in patients with type 2 diabetes mellitus and monotherapy failure.
- Trial name
- NCT00941161
- Testing
- metformin/glimepiride combination, metformin, glimepiride
- Where
- Mexico
- Volunteers
- 28 people
- Sponsor
- Laboratorios Silanes S.A. de C.V.
Diabetes Mellitus, Type 2
Opposing Step-by-step Insulin Reinforcement to Intensified Strategy
Primary objectives : To show the non inferiority in terms of efficacy (HbA1c) of insulin glargine plus metformin combined with 1 to 3 bolus of insulin glulisine introduced progressively (Arm 2) compared with insulin glargine plus…
- Trial name
- OSIRIS (NCT00174642)
- Testing
- Insulin Glargine, Insulin Glulisine, Metformin
- Where
- 18 sites in Belgium, France and 16 more
- Volunteers
- 811 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
Observational Study of Glycaemic Control in Patients Uncontrolled on Oral Antidiabetic Agents and Starting With 1 (Once) Daily Levemir® (Insulin Detemir) as the Treatment of Type 2 Diabetes Mellitus
This study is conducted in Europe. An observational study evaluating glycaemic control in patients using Levemir® as initiation insulin therapy as the treatment of type 2 diabetes in Slovakia.
- Trial name
- START (NCT00687284)
- Testing
- insulin detemir
- Where
- Slovakia
- Volunteers
- 2,188 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Comparing Intensive and Standard Training for Human Insulin Inhalation Powder (HIIP)
The purpose of this study is to compare intensive and standard training for human insulin inhalation powder in patients with type 2 diabetes.
- Trial name
- IDAP (NCT00099515)
- Testing
- LY041001 (HIIP)
- Where
- 6 sites in United States, Argentina and 2 more
- Volunteers
- 97 people
- Sponsor
- Eli Lilly and Company
Diabetes Type 2
Better Diabetes Control, Quality - Educate to Achieve Compliance.
Prospective study to evaluate the impact of an educational programme about diabetes, comparing to normal clinical practice, on treatment compliance and disease control of people with type 2 diabetes followed in the primary care…
- Trial name
- MINERVA (NCT01728714)
- Where
- 5 sites in Portugal
- Volunteers
- 227 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes
The purpose of this study is to assess the effects of 2 doses of LY2189265 on blood pressure and heart rate using 24-hour ambulatory blood pressure monitoring (ABPM), in participants with type 2 diabetes mellitus treated with…
- Trial name
- NCT01149421
- Testing
- LY2189265
- Where
- 76 sites in United States, Argentina and 6 more
- Volunteers
- 755 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.